McLean-based Science Applications International Corp., which announced plans in August to split off part of its operations into a separate publicly traded company, has decided on a name for the new business.
The spinoff, which will focus on national security, health and engineering, will be called Leidos.
This chart shows the pharmaceutical drugs with the most patents still in force.
The drugs with the most active patents are COMBIVENT RESPIMAT, KALETRA, ADVAIR HFA,FLOVENT HFA, VIVITROL, THALOMID, VYVANSE, REVLIMID, VENTOLIN HFA, andCHILDREN’S ALLEGRA ALLERGY.
The Association of University Research Parks (AURP), the world’s leading network of university research, science and technology park professionals, invites you to share your knowledge, expertise and experience by presenting at the 2013 International Conference in Philadelphia, Pennsylvania. This year’s theme is Inventing the Future.
Proven engines for economic growth and development, university research parks influence their communities in significant ways. AURP’s 2013 annual conference, hosted by The University City Science Center, will feature experts who will examine university research park best practices and the strategies which will develop a knowledge-based economy by increasing ties between university, research parks, government, and industry partners.
Interesting approaches and creative solutions to challenges surrounding this topic are sought for presentations.
Rare Disease Day, held each year on February 28, was established to raise awareness about the estimated 7,000 rare diseases that affect about 25 million Americans. To mark the occasion in 2013, the NIH will host a free, two-day public event beginning on this day to focus on rare diseases research and advocacy activities supported by several government agencies.
The National Center for Advancing Translational Sciences (NCATS) Office of Rare Diseases Research (ORDR) and the NIH Clinical Center are organizing and hosting the event. Others involved include the U.S. Food and Drug Administration and Agency for Healthcare Research Quality, and patient organizations, such as the Genetic Alliance and National Organization for Rare Disorders. Register and learn more at https://events-support.com/events/Rare_Disease_Day .
The young Leiden-based biotech company Mimetas has closed an agreement with a regional development company from the state of Maryland, USA. Biohealth Innovation Inc., in which regional governments, universities and companies collaborate, will assist in setting up a US branch to find customers and business partners for Mimetas in the USA.
Johns Hopkins University Applied Physics Laboratory has won a potential 10-year, $4,904,853,263 U.S. Navy for research, development and engineering work throughout the Defense Department.
The contract includes a five-year option for review and approval by the assistant Navy secretary for research, development and acquisition and the assistant defense secretary for research and evaluation, the Defense Department said Feb. 15.
Psyadon Pharmaceuticals has spent nine months working to enroll the 18 patients it needs for its phase 3 clinical trial involving its treatment for Tourette syndrome.
The Germantown company’s candidate, ecopipam, also targets Lesch-Nyhan disease, a genetic disorder that affects as many as 1,000 Americans, disrupting their ability to walk and causing self-mutilation.
Although Psyadon usually is not directly involved in its clinical trials — it usually uses companies called contract research organizations, which conduct trials for drug makers — it often tracks disease-related patient advocacy groups and sometimes uses this information to raise awareness of the trial, said CEO Richard Chipkin.
Leaders of several Richmond-area biotechnology-related companies said Thursday that they foresee personalized medicine as a major force driving the industry’s growth, but access to capital for small firms with good ideas remains a challenge.
“Life sciences is really the big, huge growth industry,” said Mike Grisham, the chief executive officer of GPB Scientific, a Richmond-based company focused on using microchip technology in health and life-science research.
The National Science Foundation said today that it will fund a major expansion of its Innovation Corps program, an effort to teach NSF-funded university researchers how to build profitable startups around their technologies.
In its initial stages, the two-year-old “I-Corps” program has been flying researchers to Stanford University, the University of Michigan, and Georgia Tech for prototype versions of the “Lean Launchpad” course originally developed at Stanford by serial entrepreneur and startup guru Steve Blank. Now the program is spreading to nine more universities, which have been singled out for three-year grants totaling $11.2 million.
The health care industry is undergoing major surgery. At the center of these operations is Rock Health, a startup accelerator dedicated to the intersection of healthcare and technology. Today, at a demo event at the University of San Francisco, 14 startups presented their ideas on how to transform and improve healthcare in the U.S..
Dr. Aenor Sawyer, an associate clinical professor at UCSF, said during her opening remarks that these companies are changing “how we take care of patients and how patients take care of themselves.” Whether it is managing secondary care, untangling the confusing labyrinth of insurance, or encouraging healthy lifestyle habits, these startups are holding the scalpels.
